Jakarta, CNBC Indonesia – New news coming from Brazil. Sinovac’s vaccine, CoronaVac, is said to be less effective against the corona variant detected in the country, Gamma.
Launch AFP, the researchers said the antibodies produced by the vaccine did not work well. While Gamma can infect someone who has been infected and recovers.
“The virus can potentially circulate in vaccinated individuals, even in areas with high vaccination rates,” said study authors from Brazil’s Campinas University, in a study published in The Lancet Microbe, Friday (9/7/2021).
The study was conducted in small groups. By looking at antibodies in 53 people who were vaccinated and 21 people who had been infected with the virus before.
In the already vaccinated group, 18 people received only one dose of CoronaVac, while 20 people received a second injection recently. The rest, 15 people, have been vaccinated with CoronaVac in August 2020.
It was found that Gamma was able to escape the antibodies of almost all participants who received only one dose, as well as those who were vaccinated in 2020. The antibodies from those who had just been vaccinated were effective, but less effective than previous strains of the virus.
The study also found that antibodies produced by previous infections must be nine times higher to prevent infection by Gamma than to prevent disease of the previous type. The authors say the results mean people who have survived Covid-19 cases could be reinfected.
But they say because clinical trials have shown that the vaccine is effective in preventing severe illness and death, it could be that the immune response is more complex. The CoronaVac vaccine itself was approved by the WHO in June 2021, where the agency said the vaccine’s efficacy was 51% against symptomatic disease and 100% against hospitalization.
(boss / boss)
– .
